Topas Therapeutics is a Hamburg- clinical-stage biotechnology company pioneering a novel approach to treat autoimmune and immune-mediated diseases. Our proprietary Topas Platform leverages antigen-coupled nanoparticles to target liver sinusoidal endothelial cells, inducing a tolerogenic immune response. This innovative approach has the potential to address a wide range of autoimmune diseases, including celiac disease. With promising results from our Phase 2a clinical trial in celiac d...